

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all previous versions and listings of claims.

1-22. (Canceled)

23. (Previously Presented) An isolated protein comprising amino acid residues 1 to 353 of SEQ ID NO:11.

24. (Previously Presented) The protein of claim 23 which comprises a heterologous polypeptide sequence.

25. (Previously Presented) A composition comprising the protein of claim 23 and a pharmaceutically acceptable carrier.

26. (Previously Presented) An isolated protein produced by the method comprising:
(a) expressing the protein of claim 23 by a cell; and
(b) recovering said protein.

27. (Previously Presented) An isolated protein comprising the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 203502.

28. (Previously Presented) The protein of claim 27 which comprises a heterologous polypeptide sequence.

29. (Previously Presented) A composition comprising the protein of claim 27 and a pharmaceutically acceptable carrier.

30. (Previously Presented) An isolated protein produced by the method comprising:
(a) expressing the protein of claim 27 by a cell; and
(b) recovering said protein.

31. (Previously Presented) An isolated protein comprising a first polypeptide at least 90% identical to a second polypeptide consisting of amino acid residues 1 to 353 of SEQ ID NO: 11, wherein said first polypeptide binds hyaluronan.

32. (Previously Presented) The isolated protein of claim 31 wherein said first polypeptide is at least 95% identical to said second polypeptide.

33. (Previously Presented) The protein of claim 31 which comprises a heterologous polypeptide sequence.

34. (Previously Presented) A composition comprising the protein of claim 31 and a pharmaceutically acceptable carrier.

35. (Previously Presented) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 31 by a cell; and
- (b) recovering said protein.

36. (Previously Presented) An isolated protein comprising a first polypeptide at least 90% identical to a second polypeptide consisting of the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 203502, wherein said first polypeptide binds hyaluronan.

37. (Previously Presented) The isolated protein of claim 36 wherein said first polypeptide is at least 95% identical to said second polypeptide.

38. (Previously Presented) The protein of claim 36 which comprises a heterologous polypeptide sequence.

39. (Currently Amended) A composition comprising the protein of claim ~~[[43]]~~36 and a pharmaceutically acceptable carrier.

40. (Previously Presented) An isolated protein produced by the method comprising:
- (a) expressing the protein of claim 36 by a cell; and
 - (b) recovering said protein.
41. (Previously Presented) An isolated protein consisting of at least 10 contiguous amino acid residues of amino acid residues 1 to 353 of SEQ ID NO:11.
42. (Previously Presented) The isolated protein of claim 41 which consists of at least 20 contiguous amino acid residues of amino acid residues 1 to 353 of SEQ ID NO:11.
43. (Previously Presented) The isolated protein of claim 41 which consists of at least 30 contiguous amino acid residues of amino acid residues 1 to 353 of SEQ ID NO:11.
44. (Previously Presented) The isolated protein of claim 41 which consists of at least 50 contiguous amino acid residues of amino acid residues 1 to 353 of SEQ ID NO:11.
45. (Previously Presented) The protein of claim 41 which comprises a heterologous polypeptide sequence.
46. (Previously Presented) A composition comprising the protein of claim 41 and a pharmaceutically acceptable carrier.
47. (Previously Presented) An isolated protein produced by the method comprising:
- (a) expressing the protein of claim 41 by a cell; and
 - (b) recovering said protein.
48. (Previously Presented) An isolated protein consisting of at least 10 contiguous amino acid residues of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 203502.

49. (Previously Presented) The isolated protein of claim 48 which consists of at least 20 contiguous amino acid residues of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 203502.
50. (Previously Presented) The isolated protein of claim 48 which consists of at least 30 contiguous amino acid residues of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 203502.
51. (Previously Presented) The isolated protein of claim 48 which consists of at least 50 contiguous amino acid residues of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 203502.
52. (Previously Presented) The protein of claim 48 which comprises a heterologous polypeptide sequence.
53. (Previously Presented) A composition comprising the protein of claim 48 and pharmaceutically acceptable carrier.
54. (Previously Presented) An isolated protein produced by the method comprising:
- (a) expressing the protein of claim 48 by a cell; and
 - (b) recovering said protein.
55. (Previously Presented) An isolated polypeptide consisting of a contiguous amino acid sequence selected from the group consisting of:
- (a) amino acids 7 to 15 of SEQ ID NO:11;
 - (b) amino acids 22 to 30 of SEQ ID NO:11;
 - (c) amino acids 31 to 39 of SEQ ID NO:11;
 - (d) amino acids 61 to 69 of SEQ ID NO:11;
 - (e) amino acids 70 to 78 of SEQ ID NO:11;
 - (f) amino acids 93 to 101 of SEQ ID NO:11;
 - (g) amino acids 107 to 115 of SEQ ID NO:11;

- (h) amino acids 120 to 128 of SEQ ID NO:11;
- (i) amino acids 135 to 143 of SEQ ID NO:11;
- (j) amino acids 148 to 156 of SEQ ID NO:11;
- (k) amino acids 193 to 201 of SEQ ID NO:11; and
- (l) amino acids 229 to 237 of SEQ ID NO:11.

56. (Previously Presented) The polypeptide of claim 55 wherein said amino acid sequence is (a).

57. (Previously Presented) The polypeptide of claim 55 wherein said amino acid sequence is (b).

58. (Previously Presented) The polypeptide of claim 55 wherein said amino acid sequence is (c).

59. (Previously Presented) The polypeptide of claim 55 wherein said amino acid sequence is (d).

60. (Previously Presented) The polypeptide of claim 55 wherein said amino acid sequence is (e).

61. (Previously Presented) The polypeptide of claim 55 wherein said amino acid sequence is (f).

62. (Previously Presented) The polypeptide of claim 55 wherein said amino acid sequence is (g).

63. (Previously Presented) The polypeptide of claim 55 wherein said amino acid sequence is (h).

64. (Previously Presented) The polypeptide of claim 55 wherein said amino acid sequence is (i).
65. (Previously Presented) The polypeptide of claim 55 wherein said amino acid sequence is (j).
66. (Previously Presented) The polypeptide of claim 55 wherein said amino acid sequence is (k).
67. (canceled)
68. (Previously Presented) The polypeptide of claim 55 wherein said amino acid sequence is (l).
69. (Previously Presented) The polypeptide of claim 55, wherein said polypeptide is fused to a heterologous polypeptide sequence.
70. (Previously Presented) A composition comprising the polypeptide of claim 55 and a pharmaceutically acceptable carrier.
71. (Previously Presented) An isolated polypeptide produced by the method comprising:
- (a) expressing the polypeptide of claim 55 by a cell; and
 - (b) recovering said polypeptide.
72. (Previously Presented) An isolated polypeptide consisting of a contiguous amino acid sequence selected from the group consisting of:
- (a) amino acids 51 to 100 of SEQ ID NO:11;
 - (b) amino acids 105 to 150 of SEQ ID NO:11;
 - (c) amino acids 151 to 200 of SEQ ID NO:11; and
 - (d) amino acids 121 to 215 of SEQ ID NO:11.

73. (Previously Presented) The polypeptide of claim 72 wherein said amino acid sequence is (a).
74. (Previously Presented) The polypeptide of claim 72 wherein said amino acid sequence is (b).
75. (Previously Presented) The polypeptide of claim 72 wherein said amino acid sequence is (c).
76. (canceled)
77. (Previously Presented) The polypeptide of claim 72 wherein said amino acid sequence is (d).
78. (Previously Presented) The polypeptide of claim 72, wherein said polypeptide is fused to a heterologous polypeptide sequence.
79. (Previously Presented) A composition comprising the polypeptide of claim 72 and a pharmaceutically acceptable carrier.
80. (Previously Presented) An isolated polypeptide produced by the method comprising:
- (a) expressing the polypeptide of claim 72 by a cell; and
 - (b) recovering said polypeptide.

AMENDMENTS TO THE DRAWINGS

Please replace the originally filed drawings of Figures 1A-12 (29 sheets) with the Replacement Sheets of Drawings of Figures 1A-12B (66 sheets) submitted herewith.